SSG
CTIC

Summit Securities Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Summit Securities Group’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,000
Closed -$90K – 1437
2022
Q4 		$90K Buy
+15,000
New +$81.9K ﹤0.01% 617

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Summit Securities Group's CTIC Position: Q1 2023 in Review

Summit Securities Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 15,000 shares — an estimated $90K sold.

Summit Securities Group first reported a position in CTIC in Q4 2022 and held it in 1 quarter. The position peaked at $90K in Q4 2022. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

  • Summit Securities Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
  • Summit Securities Group sold 15,000 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $90K.
  • Summit Securities Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2022 and held it in 1 quarter.
  • Summit Securities Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $90K in Q4 2022.
  • 133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on Summit Securities Group's 13F filing for Q1 2023, filed 12 May 2023.